ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MMG Medical Mktg

3.75
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Medical Mktg LSE:MMG London Ordinary Share GB0004150685
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.75 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Response to press comments

10/10/2008 1:35pm

UK Regulatory


    RNS Number : 5965F
  Medical Marketing Int'l Group PLC
  10 October 2008
   
    Response to press comments

    Friday 10 October 2008 - Medical Marketing International Group plc ("MMI" or the "Company") (AIM:MMG), the life sciences company focused
on the development of drugs for cancer, wishes to clarify that, despite press comments, the Company is not aware of any additional results
to be notified in relation to the University of Southampton Phase I/II clinical study in prostate cancer. The most recent study results were
notified by the Company on 4 April 2008.


    Enquiries:

    
 Medical Marketing International Group plc                           
 Phil Cartmell, Non-executive Chairman      Tel: +44 (0) 1223 477 677
 Mark Burton, Chief Technical Officer                                
 Rob Sprawson, Chief Financial Officer                               
 
    
 FinnCap                                               
 Sam Smith/Charlie Cunningham  Tel: +44 (0)20 7600 1658
 
    
 Financial Dynamics                                 
 David Yates/Emma Thompson  Tel: +44 (0)20 7831 3113





    About MMI
    Medical Marketing International Group plc ("MMI") is a life sciences company that identifies, acquires and develops world-class
compounds and technologies for the treatment of cancer. The Company manages the preclinical and early clinical development of drug
candidates before pursuing licensing partners to manage late-stage development. Please visit www.mmigroup.co.uk for further information.

    Notwithstanding the inclusion on this release by MMI of a website address and/or another electronic address, MMI does not accept any
notices or any other documents or communication via its website or other electronic address. All such notices, documents or communication
shall be in hard copy format only. Accordingly the provisions of section 333 Companies Act 2006 allowing persons to communicate with MMI
electronically shall not apply to MMI.
    -ends-


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RSPBDBDGDXBGGIG

1 Year Medical Mktg Chart

1 Year Medical Mktg Chart

1 Month Medical Mktg Chart

1 Month Medical Mktg Chart

Your Recent History

Delayed Upgrade Clock